Investigational drug · Phase 2
CTX-471
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CTX-471"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTX-471", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neuroendocrine Neoplasm
- Neuroendocrine Carcinomas
- Neuroendocrine Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CTX-471" as an intervention, largest first.
Compass TherapeuticsIndustry
NCT03881488 · 100 participants · Start May 17, 2019 · Primary completion May 21, 2025
Drug: CTX-471; Pembrolizumab (KEYTRUDA®) · For: Locally Advanced Solid Tumor; Metastatic Cancer; Non-small Cell Lung Cancer and 4 more
Sites: Ocala, Florida; Port Saint Lucie, Florida; Boston, Massachusetts · 10 sites in all
Compass TherapeuticsIndustry
NCT07684170 · 58 participants (planned) · Start Nov 2026 · Primary completion Sep 2028
Drug: CTX-471 · For: Neuroendocrine Neoplasm; Neuroendocrine Carcinomas; Neuroendocrine Tumors
Sites: St Louis, Missouri; Seattle, Washington
Washington University School of MedicineAcademic, hospital or other
NCT07392957 · 54 participants (planned) · Start Jun 16, 2026 · Primary completion Jun 30, 2029
Drug: CTX-009; CTX-471 · For: Glioblastoma
Sites: St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U, Guzman W, Wolf B, et al. · JCI Insight 2020
Also in development for Neuroendocrine Neoplasm
- CRN09682Phase 21 trial
Crinetics Pharmaceuticals Inc. · SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.